Effects of osteoprotegerin administration on osteoclast differentiation and trabecular bone structure in osteoprotegerin-deficient mice

Journal of Electron Microscopy

Volumn 54, Issue 5, 2005, Pages 467-477

  Yamazaki, Hiroko ^a   Sasaki, Takahisa ^a  

^a SHOWA UNIVERSITY   (Japan)

Author keywords

Bone resorption; Cartilage resorption; Osteoclast; Osteoprotegerin deficient mouse; Type I collagen; Type II collagen

Indexed keywords

ACID PHOSPHATASE; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; CELL RECEPTOR; COLLAGEN TYPE 1; COLLAGEN TYPE 2; GLYCOPROTEIN; ISOENZYME; OSTEOPROTEGERIN; TARTRATE-RESISTANT ACID PHOSPHATASE; TNFRSF11B PROTEIN, MOUSE; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL; ARTICLE; BONE; BONE MATRIX; CARTILAGE; CELL DIFFERENTIATION; CYTOLOGY; GENETICS; GROWTH PLATE; METABOLISM; MOUSE; MOUSE MUTANT; OSTEOCLAST; PHYSIOLOGY; TRANSMISSION ELECTRON MICROSCOPY; ULTRASTRUCTURE;

ACID PHOSPHATASE; ANIMALS; BONE AND BONES; BONE MATRIX; CARTILAGE; CELL DIFFERENTIATION; COLLAGEN TYPE I; COLLAGEN TYPE II; GLYCOPROTEINS; GROWTH PLATE; ISOENZYMES; MICE; MICE, KNOCKOUT; MICROSCOPY, ELECTRON, TRANSMISSION; OSTEOCLASTS; OSTEOPROTEGERIN; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR;

BONE; COLLAGEN; MAMMALS; PLATES (STRUCTURAL COMPONENTS);

BONE RESORPTION; CARTILAGE RESORPTION; GROWTH PLATE; OSTEOCLAST; OSTEOPROTEGERIN; OSTEOPROTEGERIN-DEFICIENT MOUSE; TRABECULAR BONE STRUCTURES; TYPE I COLLAGEN; TYPE II COLLAGENS; TYPE-I COLLAGEN;

CARTILAGE;

EID: 29444461337     PISSN: 00220744     EISSN: 14779986     Source Type: Journal    
DOI: 10.1093/jmicro/dfi066     Document Type: Article

References (36)

1. Fuller K, Wong B, Fox S, Choi Y, and Chambers TJ (1998) TRANCE is necessary and sufficient for osteoclast-mediated activation of bone resorption in osteoclasts. J. Exp. Med. 188: 997-1001.
2. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Hsu H, Sullivan J, Hakins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senalddi G, Guo J, Delaney J, and Boyle WJ (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: 165-176.
3. Matsuzaki K, Udagawa N, Takahashi N, Yamaguchi K, Yasuda H, Shima N, Moronaga T, Toyama Y, Yabe Y, Higashio K, and Suda T (1998) Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures. Biochem. Biophys. Res. Commun. 246: 199-204.
4. 2, or parathyroid hormone in the microenvironment of bone. Biochem. Biophys. Res. Commun. 246: 337-341.
5. Yasuda H, Shima N, Nakagawa N, Mochizuki S, Yano,K, Fujise N, Sato Y, Goto M, Yamaguchi K, Kuriyama M, Kanno T, Murakami A, Tsuda E, Morinaga T, and Higashio K (1998) Identity of osteoclastogenesis inhibitory factor (OCIF) and Osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139: 1329-1337.
6. Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, Tan HL, Elliott G, Kelley MJ, Sarosi I, Wang L, Xia XZ, Elliott R, Chiu L, Black T, Scully S, Capparelli C, Morony S, Shimamoto G, Bass MB, and Boyle WJ (1999) Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc. Natl Acad. Sci. USA, 96, 3540-3545.
7. Jimi E, Akiyama S, Tsurukai T, Okahashi N, Kobayashi K, Udagawa N, Nishimura T, Takahashi N, and Suda T (1999) Osteoclast differentiation factor act as a multifunctional regulator in murine osteoclast differentiation and function. J. Immunol. 163: 434-442.
8. Takami M, Woo JT, and Nagai K (1999) Osteoblastic cells induce fusion and activation of osteoclasts through a mechanism independent of macrophage-colony-stimulating factor production. Cell Tissue Res. 298: 327-334.
9. Udagawa N, Takahashi N, Jimi E, Matsuzaki K, Tsurukai T, Itoh K, Nakagawa N, Yasuda H, Goto M, Tsuda E, Higashio K, Gillespie MT, Martin TJ, and Suda T (1999) Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation facor/RANKL but not macrophage colony-stimulating factor. Bone 25: 517-523.
10. Dougall WC, Glaccum M, Charrier K, Rohrback K, Brasel K, De Smedt T, Daro E, Smith J, Tometsko ME, Maliszewski CR, Armstrong A, Shen V, Bain S, Cosman D, Anderson D, Morrissey PJ, Peschon JJ, and Schuh J (1999) Rank is essential for osteoclast and lymph node development. Genes Dev. 13: 2412-2424.
11. Kong YY, Yoshida H, Sarosi HL, Tan E, Timms C, Capparelli S, Moony A, Oliveira - dos-Santos G, Van A, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM (1999) OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397: 315-323.
12. Li J, Sarosi I, Yan XQ, Morony S, Capparelli C, Tan HL, McCabe S, Elliott R, Scully S, Van G, Kaufman S, Juan SC, Sun Y, Tarpley J, Martin L, Christensen K, McCabe J, Kostenuik P, Hsu H, Fretcher F, Dunstan CR, Lacey DL, and Boyle WJ (2000) RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc. Natl Acad. Sci. USA 97: 1566-1571.
13. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Amgen EST Program, and Boyle WJ (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89: 309-319.
14. Tsuda E, Goto M, Mochizuki S, Yano K, Kobayashi F, Morinaga T, and Higashio K (1997) Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem. Biophys. Res. Commun. 234: 137-142.
15. 3 have ruffled borders and resorb dentine. Anat. Rec. 224: 279-291.
16. Akatsu T, Murakami T, Nishikawa M, Ono K, Shinomiya N, Tsuda E, Mochizuki S, Yamaguchi K, Kinosaki M, Higashio K, Yamamoto M, Motoyoshi K, and Nagata N (1998) Osteoclastogenesis inhibitory factor suppresses osteoclast survival by interfering in the interaction of stromal cells with osteoclast. Biochem. Biophys. Res. Commun. 250: 229-234.
17. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda A, Morinaga T, Higashio K, Udagawa N, Takahashi N, and Suda T (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl Acad. Sci. USA 95: 3597-3602.
18. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, and Simonet WS (1998) Osteoprotegerin- deficient mice develop early onset osteopororsis and arterial calcification. Genes Dev. 12: 1260-1268.
19. Mizuno A, Amizuka N, Irie K, Murakami A, Fujise N, Kanno T, Sato Y, Nakagawa N, Yasuda H, Mochizuki S, Gomibuchi T, Yano K, Shima N, Washida N, Tsuda E, Morinaga T, Higashio K, and Ozawa H (1998) Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem. Biophys. Res. Commun. 247: 610-615.
20. Yano K, Tsuda E, Washida N, Kobayashi F, Goto M, Harada A, Ikeda K, Higashio K, and Yamada Y (1999) Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J. Bone Miner. Res. 14: 518-527.
21. Amizuka N, Shimomura J, Li M, Seki Y, Oda K, Henderson JE, Mizuno A, Ozawa H, and Maeda T (2003) Defective bone remodeling in osteoprotegerin- deficient mice. J. Electron Microsc. 52: 503-513.
22. Kawana F and Sasaki T (2003) Osteoclast differentiation and characteristic trabecular bone formation during growth plate destruction in osteoprotegerin-deficient mice. J. Electron Microsc. 52: 515-525.
23. Whyte MP, Obrecht SE, Finnegan PM, Jones JL, Podgornik MN, McAlister WH, and Mumm S. (2002) Osteoprotegerin deficiency and juvenile Paget's disease. N. Engl. J. Med. 347: 175-184.
24. Bateman TA, Dunstan CR, Ferguson VL, Lacey DL, Ayers RA, and Simske SJ (2000) Osteoprotegerin mitigates tail suspension-induced osteopenia. Bone 26: 443-449.
25. Shimizu-Ishiura T, Kawana F, and Sasaki T (2002) Osteoprotegerin administration reduces femoral bone loss in ovariectomized mice via impairment of osteoclast structure and function. J. Electron Microsc. 51: 315-325.
26. Shiotani A, Takami M, Itoh K, Shibasaki Y, Sasaki T (2002) Regulation of osteoclast differentiation and function by receptor activator NFκB ligand and osteoprotegerin. Anat. Rec. 268: 137-146.
27. Murakami T, Yamamoto M, Yamamoto M, Ono K, Nishikawa M, Nagata N, Motoyoshi K, and Akatsu T (1998) Transforming growth factor-β1 increases mRNA levels of osteoclastogenesis inhibitory factor in osteoblastic/stromal cells and inhibits the survival of murine osteoclast-like cells. Biochem. Biophys. Res. Commun. 252: 747-752.
28. Nakamura M, Udagawa N, Matsuura S, Mogi M, Nakamura H, Horiuchi H, Saito N, Hiraoka Y, Kobayashi Y, Takaoka K, Ozawa H, Miyazawa H, and Takahashi N (2003) Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption. Endocrinology 144: 5441-5449.
29. Goto T, Yamaza T, and Tanaka T (2003) Cathepsins in the osteoclast. J. Electron Microsc. 52: 551-558.
30. Delaisse JM, Andersen TL, Engsig MT, Henriksen K, Troen T and Blavier L (2003) Matrix metalloproteinases (MMP) and cathepsin K contribute differently to osteoclastic activities. Microsc. Res. Techn. 61: 504-513.
31. Vu TH, Shipiey JM, Bergers G, Berger JE, Helms JA, Hanahan D, Shapiro SD, Senior RM, and Werb Z (1998) MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 93: 411-422.
32. 3 have ruffled borders and resorb dentine. Anat. Rec. 224: 279-291.
33. Nakamura I, Gailit J, and Sasaki T (1996) Osteoclast integrin is present in the clear zone and contributes to cellular polarization. Cell Tissue Res. 286: 507-515.
34. Sahara T, and Sasaki T (2001) Effects of Brefeldin-A: potent inhibitor of intracellular protein transport on ultrastructure and resorptive function of cultured osteoclasts. Anat. Rec. 263: 127-138.
35. +-ATPase and lysosomal cysteine proteinase, cathepsin K, in osteoclasts. Anat. Rec. 270A: 152-161.
36. O'Brien EA, Williams JHH, and Marshall MJ (2001) Osteoprotegerin is produced when prostaglandin synthesis is inhibited causing osteoclasts to detach from the surface of mouse parietal bone and attach to the endocranial membrane. Bone 28: 208-214.